Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Wuhan Easy Diagnosis Biomedicine Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Wuhan Easy Diagnosis Biomedicine Co's long-term debt to total assets ratio declined from Mar. 2023 (0.00) to Mar. 2024 (0.00). It may suggest that Wuhan Easy Diagnosis Biomedicine Co is progressively becoming less dependent on debt to grow their business.

Wuhan Easy Diagnosis Biomedicine Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Wuhan Easy Diagnosis Biomedicine Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Easy Diagnosis Biomedicine Co LT-Debt-to-Total-Asset Chart

Wuhan Easy Diagnosis Biomedicine Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Wuhan Easy Diagnosis Biomedicine Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Wuhan Easy Diagnosis Biomedicine Co LT-Debt-to-Total-Asset Calculation

Wuhan Easy Diagnosis Biomedicine Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	18.253	/	7386.6
	=	0.00

Wuhan Easy Diagnosis Biomedicine Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	17.807	/	7240.838
	=	0.00

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Wuhan Easy Diagnosis Biomedicine Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075

Website

http://www.mdeasydiagnosis.com

Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.

Executives

Wang Rui	Directors, executives
Wang Jian Fei	Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines